TP53 and head and neck squamous cell carcinoma: Gendicine delivers an exogenous gene expressing p53 and is approved by the State Food and Drug Administration (SFDA) of China in 2013 to treat squamous cell carcinoma of the head and neck (HNSCC) in combination with chemotherapy, which has been used to treat over 30,000 patients [38,39,40,41].